Wall Street's main indexes closed modestly higher on Wednesday as a retreat in government bond yields boosted risk appetite, led by a record rally in Moderna shares after a cancer therapy trial…
Moderna has begun a first human trial of an experimental vaccine against Bundibugyo ebolavirus, a strain with no approved vaccine. Health Canada cleared the early-stage study, and the first volunteers have received…
The U.S. Food and Drug Administration has approved Moderna’s mFlusiva seasonal flu vaccine for adults aged 50 and older. It received traditional approval for people aged 50 to 64 and accelerated approval…
